Mukupera kwa2015, Doron Broman ane makore makumi mana nemana akaonekwa aine kenza yepancreatic - uye akashamisika kuona kuti kenza yake yepancreatic yakanga yave nebundu hombe pachiropa. Akatarisana nenguva yekupona yemwedzi mishoma chete, Broman akafunga kushandisa nguva shoma ari munzvimbo chaiyo.
Broman was diagnosed with metastatic pancreatic cancer pazera re44
Iye ari Miami-based real estate anovandudza uye imba yake iri muBoston. Mushure mekuita research online, akafunga kunorapwa kuDana-Farber. Chiremba wake Kimmie Ng, MD, MPH, mutungamiriri wekutsvagisa kwekiriniki paGastrointestinal Cancer Treatment Center, anokurudzira chirongwa cheFOLFIRINOX, iyo ndiyo yakasimba kwazvo musanganiswa chemotherapy yepancreatic cancer. Pancreatic cancer ndiyo inonyanyozivikanwa kurapwa.
Broman aibhururuka kubva kuMiami kuenda kuBoston vhiki mbiri dzese kuti arapwe. Chakashamisa munhu wese, huipi hwepancreas nechiropa zvakatanga kudzikira nekukurumidza.
“This is the most significant response,” Ng sighed. “Several tumors almost completely disappeared after chemotherapy. This makes us wonder if there is a molecular mutation in his tumarara that makes it particularly sensitive to FOLFIRINOX.
Oncologists vakatanga kutsvaga zvisina kujairika mamorekuru shanduko kana shanduko mukukodha bundu reDNA, nekuti vakaona murwere achivandudza zvakanyanya kenza zvinodhaka, uye mushonga unowanzove nemhinduro ine mwero kana kusabatsira kune vamwe varwere vane chirwere ichi. These types of patients are called “special responders.” In the era of precision medicine, sequencing DNA from cancers of special responders may identify rare mutations, making patients ‘tumors extremely sensitive to specific drugs.
Kenza yaBroman yakapindura zvakanyanya kurapwa kwakakurudzirwa naKimmie Ng, MD.
Broman happened to arrive at Dana-Farber treatment just after Ng and her colleagues just started a new research protocol, allowing patients to perform additional biopsies to obtain genetic material that can be treated with precision medicine. Broman agreed. The entire exon sequence of his tumor DNA revealed mutations in the BRCA2 gene. When this mutation is inherited by women, it will greatly increase the risk of breast and ovarian kenza. But Broman did not inherit the BRCA2 shanduko -zvakangoita izvo pane imwe nguva muhupenyu hwake, maseru ake epancreatic akasarudzika akave nekuchinja uku.
BRCA2 mutations can interfere with a cell’s ability to repair DNA damage, causing the cell to destroy itself. Cancer cells with BRCA2 mutations are particularly sensitive to platinum-based chemotherapeutic drugs based on DNA damage, which is part of the FOLFIRINOX protocol. This may explain why Broman ‘s cancer has been hit so successfully.
Mushure mematanho gumi nematanhatu ekurapwa neFOLFIRINOX, Broman akapindura mushe pakurapa pamwe nemhedzisiro senge kurasikirwa bvudzi uye kukuvara kwetsinga, saka timu yake yekurapa yakafunga kuishandura kuita mushonga wakanangwa unonzi olaparib unonzi PARP inhibitor (Lynparza) inogona kutadzisa DNA kugadzirisa kugadzirisa. .
"Olaparib inogamuchirwa kuti igare nhaka BRCA-2 kenza inochinja-inoenderana nekenza," akadaro Ng. "Zvisinei, mune mamwe maronda akachinjika (asiri efa) BRCA2, hapana ruzivo rwechokwadi nezvebasa rayo."
Therefore, Broman stopped FOLFIRINOX and now takes 12 olabally daily. He said that there will be no side effects. Six months after his new protocol, MRI and CT scans showed no cancer recurrence, and pancreatic cancer blood biomarker levels remained within normal limits. Ng said his plan is to keep him taking olabally indefinitely, as long as it keeps the cancer under control and has few side effects.
Broman akati: "Ndiri kunyatsofara". Akanamata mazuva ese kubva paakazviona. Iye achangobva kuenda kuEurope nekuIsrael kwaakaberekerwa. “Ndakaita zviri nani zvikuru kupfuura zvandaitarisira. Ndiri kunzwa zvakanaka, vhudzi rangu rakadzoka, ndiri mutano, ndinofamba mamaira gumi nemaviri pazuva, Mugovera nezuva. Shamwari dzangu dzakati dzaisatenda. ”
For Ng and her colleagues, she said that Broman ‘s case “points out that precision oncology and targeted therapy based on its molecular characteristics benefit cancer patients greatly.”
